E17K substitution in AKT1 in prostate cancer.
E17K substitution in AKT1 in prostate cancer.
复制标题
DOI:
10.1038/sj.bjc.6605673
复制
发表时间:
2010-05-11
影响因子:
8.8
通讯作者:
中科院分区:
文献类型:
--
作者:
The phosphatidylinositol 3-kinase (PI3K)–AKT pathway is activated in many cancers. Mutational hotspots in AKT1 and in the regulatory and catalytic subunits of PI3K have been detected in multiple tumour types. In AKT1, the E17K substitution leads to a PI3K-independent activation of AKT1. A mutational profiling of AKT1 and of the mutational hotspots in PIK3CA and PIK3R1 was carried out in samples from primary and recurrent prostate tumours. We show that, in prostate cancer, AKT1(E17K) had a prevalence of 1.4%. The mutation seemed to be associated with a favourable clinical course but it was not associated with a specific tumour growth pattern. Activating mutations in PIK3CA or PIK3R1 were not found in prostate cancer. The E17K substitution in AKT1 is rare in prostate cancer. It seems associated with a favourable clinical outcome but not with a specific histology of the tumour.
登录
查看更多内容
影响因子:
8.8
作者:
Davies, M. A.;Stemke-Hale, K.;Tellez, C.;Calderone, T. L.;Deng, W.;Prieto, V. G.;Lazar, A. J. F.;Gershenwald, J. E.;Mills, G. B.
通讯作者:
Mills, G. B.
影响因子:
8.8
作者:
通讯作者:
--
影响因子:
50.3
作者:
Wang, SY;Gao, J;Wu, H
通讯作者:
Wu, H
影响因子:
--
作者:
Zilberman, Dorit E.;Cohen, Yoram;Rechavi, Gideon
通讯作者:
Rechavi, Gideon
DOI:
10.1126/science.1164382
发表时间:
2008-09-26
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Parsons DW;Jones S;Zhang X;Lin JC;Leary RJ;Angenendt P;Mankoo P;Carter H;Siu IM;Gallia GL;Olivi A;McLendon R;Rasheed BA;Keir S;Nikolskaya T;Nikolsky Y;Busam DA;Tekleab H;Diaz LA Jr;Hartigan J;Smith DR;Strausberg RL;Marie SK;Shinjo SM;Yan H;Riggins GJ;Bigner DD;Karchin R;Papadopoulos N;Parmigiani G;Vogelstein B;Velculescu VE;Kinzler KW
通讯作者:
Kinzler KW